Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

04/18/18
( FY )
ALS

ALS

04/09/18
( FY )
SMA

SMA

04/09/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at the 2018 Annual Cure SMA Conference
First Study of Muscle-Directed Therapy in Patients with SMA Showed Potentially Clinically Meaningful Effects on Six Minute Walk Distance and Maximal Expiratory Pressure SOUTH SAN FRANCISCO, Calif. , June 16, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced data from
Toggle Summary Cytokinetics to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif. , June 13, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at
Toggle Summary Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018
SOUTH SAN FRANCISCO, Calif. , June 08, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in an oral presentation at the 2018 Annual Cure SMA
Toggle Summary Cytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMA
ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics today announced an expanded partnership to increase education, awareness and fundraising for spinal muscular atrophy (SMA).  As a National Platinum Partner for 2018, Cytokinetics will

EVENTS

There are currently no events to display.